

Steve Ouellette, PhD, is currently a Patent Agent at Cooley LLP, where he works with biotechnology clients ranging from founders in stealth mode to public companies to develop strategies for obtaining patent protection on therapeutics, diagnostics, medical devices, and research tools. His scientific training was grounded in molecular pharmacology and focused specifically on cell-based assay development for profiling in vitro toxicology and kinase activity. He co-founded KinaSense LLC and served as Chief Technology Officer to commercialize discoveries from Dr. Laurie Parker's research group. As CTO, his duties included business model development and planning, licensing and managing University-owned intellectual property, raising startup funds, and business development activities. In addition, he has worked with many small business clients in the life sciences as a consultant, advising them on company formation, developing early-stage R&D and commercialization plans, and submitting SBIR/STTR grant applications to the NIH and NSF.